Sovaldi Archives

[The New York Times] Gilead, Maker of Hepatitis C Drug, Strikes Deal on Generics for Poor Countries

Sep 15, 2014

Gilead announced that it had struck agreements with seven Indian generic drug makers to sell lower-cost versions of its $1,000-a-pill Hepatitis C drug in poorer countries. The deals are intended to provide greater access to the medicine Sovaldi for most of the nearly 180 million infected worldwide with Hepatitis C who do not live in rich countries. Some 350,000 people die every year of Hepatitis C infections, most of them in middle- and low-income nations. Read More

[The Street] Retrophin Assailed for ‘Exorbitant’ Price Hike

Sep 10, 2014

Runaway drug pricing has become a recent hot topic, witnessed best by the media and political bashing of Gilead Sciences (GILD_) for the $1,000-per-day cost of its hepatitis C pill Sovaldi. Read More

[The Boston Globe] New Genzyme drug comes at a high price

Sep 9, 2014

There are a lot of innovative therapies with encouraging prospects and eye-popping price tags in the news lately. All of them pose hard questions about the big commercial risks drug companies must take and the enormous pricing power of medicines that can help suffering patients. Read More

[Des Moines Register] State paying for pricey pill to treat Hepatitis C

Sep 8, 2014

The state of Iowa has started paying $1,000 per pill for a new drug targeting hepatitis C, but officials don't plan to buy the medication for every person who carries the virus and qualifies for public health care. Read More

[Bloomberg] Gilead Close to Sending $84,000 Drug to Poor Countries

Sep 5, 2014

Gilead Sciences Inc. (GILD) is close to a pact with generic drugmakers to bring low-cost versions of its $84,000 hepatitis C drug Sovaldi to about 80 developing countries including India,Indonesia, and Pakistan. Read More